Johnson Peter R A, Burgess Janette K
Department of Pharmacology, The University of Sydney, NSW Australia 2006.
Curr Allergy Asthma Rep. 2004 Mar;4(2):102-8. doi: 10.1007/s11882-004-0054-9.
Asthma is a disease characterized by marked structural changes within the airway wall. These changes include deposition of extracellular matrix proteins and an increase in the numbers of airway smooth muscle cells and subepithelial fibroblasts. Both these cell types possess properties that would enable them to be involved in remodeling and inflammation. These properties include the production of a variety of cytokines; growth factors and fibrogenic mediators; proliferation, migration and release of extracellular matrix proteins; matrix metalloproteinases; and their tissue inhibitors. Airway smooth muscle and subepithelial fibroblasts are likely to be key players in the asthmatic airway pathophysiology through their interaction with each other, inflammatory cells, and other mesenchymal cells, such as the epithelium. Current asthma therapies lack the ability to completely prevent or reverse the remodeling of the airways, therefore indicating the need for new therapeutic strategies to counter this important aspect of asthma.
哮喘是一种以气道壁显著结构变化为特征的疾病。这些变化包括细胞外基质蛋白的沉积以及气道平滑肌细胞和上皮下成纤维细胞数量的增加。这两种细胞类型都具有能够使其参与重塑和炎症的特性。这些特性包括产生多种细胞因子、生长因子和促纤维化介质;细胞外基质蛋白的增殖、迁移和释放;基质金属蛋白酶及其组织抑制剂。气道平滑肌和上皮下成纤维细胞可能通过彼此之间、与炎症细胞以及其他间充质细胞(如上皮细胞)的相互作用,在哮喘气道病理生理学中发挥关键作用。目前的哮喘治疗方法缺乏完全预防或逆转气道重塑的能力,因此表明需要新的治疗策略来应对哮喘的这一重要方面。